Skip to main content

Table 3 Multivariate analysis

From: Subcellular localisation of pMEK has a different prognosis in locally advanced head and neck cancer treated with concomitant radiochemotherapy

 

DFS

OS

Variable

HR (95 % CI)

P value

HR (95 % CI)

P value

T stage (T1/2 vs T3/4)

0.82 (0.31–2.17)

0.69

0.94 (0.36–2.46)

0.90

N stage (0–1 vs 2–3)

2.34 (1.33–4.04)

0.03

2.15 (1.25–3.70)

0.06

ECOG performance status (0 vs ≥1)

1.74 (0.93–3.26)

0.08

1.67 (0.93–2.99)

0.09

P16

1.02 (0.53–1.96)

0.95

1.03 (0.54–1.96)

0.92

Nuclear pMEK

2.21 (1.14–4.30)

0.02

2.12 (1.12–3.99)

0.02

Cytoplasmic pMEK

0.48 (0.23–0.85)

0.01

0.53 (0.29–0.97)

0.04

  1. Abbreviations: CI confidence interval; DFS disease-free survival; ECOG Eastern Cooperative Oncology Group; HR hazard ratio; OS overall survival